Home › Metastatic Cancer › NCT06693687
A Study of the ApricityCare Program for Early Detection and Management of Treatment-Related Adverse Events in Patients With Cancer
Recruiting
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Age 18 years of age or older * Confirmed diagnosis of cancer * Part 1 (Run-in Phase): Only patients with prostate, kidney, and/or bladder cancer will be enrolled with either localized or metastatic disease. * Part 2 (Expansion Phase): Metastatic patients will be enrolled. Note, evaluable metastatic patients from Ppart 1 will be counted in Cohort A as described in section 8.4. * Planned to receive systemic anti-cancer therapy * Ability to understand and the willingness to sign a written informed consent document * Ability to speak, read, and understand one of the following languages: English, Spanish, Mandarin and Cantonese Chinese * Ownership of a smartphone and willingness to use it as outlined by the protocol and described in the ICF Exclusion Criteria: \- Have any medical, psychological, or social condition that, in the opinion of the investigator would preclude participation in this study (pregnancy is not exclusionary and pregnant women will be permitted to enroll in the study).
About the study
To evaluate the rate of therapy discontinuation due to toxicity (side effects) among participants with cancer using ApricityCare.
Investigators want to learn if identification of early clinical signs of irAEs with timely treatment can prevent severity progression and reduce treatment discontinuation.
What is being tested
- Metastatic Cancer (behavioral)
Sponsor: M.D. Anderson Cancer Center · Participants: 425 · Started: Dec 18, 2024
Contact the study team
- Bilal A Siddiqui, MD · Phone: (713) 563-4600
Official record on ClinicalTrials.gov — NCT06693687
Locations in the U.S.
| Texas | MD Anderson Cancer Center, Houston |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.